Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis

By: via Benzinga
Targacept, Inc. (NASDAQ: TRGT) today announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.